TAO WU to Follow-Up Studies
This is a "connection" page, showing publications TAO WU has written about Follow-Up Studies.
Connection Strength
0.088
-
Associated factors for discontinuation of statin use one year after discharge in patients with acute coronary syndrome in China. BMJ Open. 2022 09 14; 12(9):e056236.
Score: 0.025
-
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study. Leukemia. 2021 06; 35(6):1671-1682.
Score: 0.022
-
Risk-based, response-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study. Am J Hematol. 2020 09; 95(9):1047-1056.
Score: 0.022
-
Effect of primary tumor invasion on treatment and survival in extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: a multicenter study from the China Lymphoma Collaborative Group (CLCG). Leuk Lymphoma. 2019 11; 60(11):2669-2678.
Score: 0.020